Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details Narrative)

v3.19.1
Significant Accounting Policies (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 31, 2019
USD ($)
Breathalyzers
shares
Mar. 31, 2018
USD ($)
Breathalyzers
shares
Dec. 31, 2018
USD ($)
Breathalyzers
Restricted cash $ 480,000   $ 500,000
Maturities of securities less than one year    
Unrealized gain on securities $ 29,343    
Unrealized loss on securities   $ 16,843  
Marketable securities, loss (3,718) 0  
Allowances for doubtful accounts for trade receivables 611,082   606,835
Bad debt expenses 4,247 0  
Trade receivables 324,524   176,326
Depreciation expense 5,435 13,675  
Intangible assets, net 233,409   243,411
Amortization expense 10,002 42,777  
Accrued liabilities 19,504   23,179
Rebates recognized during period $ 8,698 37,544  
Income tax examination, likelihood percentage The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.    
Unrecognized tax benefits  
Income tax benefit  
Accrued for penalties and interest  
Product cost of sales 245,937 297,500  
Cost of net revenue 11,919 26,944  
Net loss attributable to common shareholders $ 916,958 $ 1,859,991  
Weighted average basic and diluted common shares outstanding | shares 12,483,209 8,956,279  
Shipping and Handling [Member]      
Product cost of sales $ 12,486 $ 13,641  
Patents, Trademarks and Customer Lists [Member]      
Intangible assets, net 3,897,635    
Intangible assets, accumulated amortization $ 3,664,226    
Sales Revenue, Net [Member]      
Concentration risk percentage 89.00%    
Concentration risk, number of customer | Breathalyzers 2 1  
Sales Revenue, Net [Member] | Customer One [Member]      
Concentration risk percentage 45.00%    
Sales Revenue, Net [Member] | Customer Two [Member]      
Concentration risk percentage 44.00%    
Trade Receivable [Member]      
Concentration risk percentage 80.00%   73.00%
Concentration risk, number of customer | Breathalyzers 3   2
Trade Receivable [Member] | Customer One [Member]      
Concentration risk percentage 49.00%   59.00%
Trade receivables $ 458,902   $ 458,902
Trade Receivable [Member] | Customer Two [Member]      
Concentration risk percentage 17.00%   14.00%
Trade receivables $ 156,988   $ 111,037
Trade Receivable [Member] | Customer Three [Member]      
Concentration risk percentage 14.00%    
Trade receivables $ 137,102    
Cost of Goods [Member]      
Concentration risk percentage 44.00%    
Concentration risk, number of supplier | Breathalyzers 2 1  
Cost of Goods [Member] | Supplier One [Member]      
Concentration risk percentage 31.00%    
Cost of Goods [Member] | Supplier Two [Member]      
Concentration risk percentage 13.00%    
Trade Payables [Member] | Two Vendors [Member]      
Concentration risk percentage 51.00%    
Concentration risk, number of supplier | Breathalyzers 2    
Trade Payables [Member] | One Vendor [Member]      
Concentration risk percentage   10.00%  
Concentration risk, number of supplier | Breathalyzers   1  
Minimum [Member]      
Normal credit terms extended to customers 30 days    
Minimum [Member] | Sales Revenue, Net [Member] | One Customer [Member]      
Concentration risk percentage   10.00%  
Minimum [Member] | Cost of Goods [Member] | One Supplier [Member]      
Concentration risk percentage   10.00%  
Maximum [Member]      
Normal credit terms extended to customers 90 days